Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice

Following curative immunotherapy of B16F10 tumors, similar to 60% of mice develop a strong antibody response against cell-surface tumor antigens. Their antisera confer prophylactic protection against intravenous challenge with B16F10 cells, and also cross-react with syngeneic and allogeneic tumor cell lines MC38, EL.4, 4T1, and CT26. We identified the envelope glycoprotein (env) of a murine endogenous retrovirus (ERV) as the antigen accounting for the majority of this humoral response. A systemically administered anti-env monoclonal antibody cloned from such a response protects against tumor challenge, and prophylactic vaccination against the env protein protects a majority of naive mice from tumor establishment following subcutaneous inoculation with B16F10 cells. These results suggest the potential for effective prophylactic vaccination against analogous HERV-K env expressed in numerous human cancers.

Automated summary

After curative immunotherapy of B16F10 tumors, around 60% of mice develop a strong antibody response against cell-surface tumor antigens, providing prophylactic protection against tumor formation. The majority of this humoral response is directed against the envelope glycoprotein of a murine endogenous retrovirus. Prophylactic vaccination against this protein can protect naive mice from tumor establishment following subcutaneous inoculation with B16F10 cells.